• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点抑制剂相关免疫不良事件可能是类固醇相关股骨头坏死的一种新的潜在病因：一例报告

Immune-related Adverse Event with Checkpoint Inhibitors Might Be an Emerging Underlying Disease of Steroid-related Osteonecrosis of the Femoral Head: A Case Report.

作者信息

Nishimura Ryosuke, Kutsuna Tatsuhiko, Kinoshita Tomofumi, Kono Kohei, Mashima Naohiko, Takao Masaki

机构信息

Department of Orthopaedic Surgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.

出版信息

J Orthop Case Rep. 2024 Aug;14(8):36-41. doi: 10.13107/jocr.2024.v14.i08.4638.

DOI:10.13107/jocr.2024.v14.i08.4638
PMID:39157500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11327667/
Abstract

INTRODUCTION

Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced metastatic and immunogenic cancers. However, these therapies could cause immune-related adverse events (irAEs), which require high-dose glucocorticoid administration.

CASE REPORT

A 52-year-old man with metastatic renal cell carcinoma received ICI therapy. Two weeks later, he suffered from severe irAEs and received glucocorticoid therapy for 13 months. Twenty-one months after the initiation of glucocorticoid administration, he presented to us with bilateral hip pain and was diagnosed with bilateral osteonecrosis of the femoral head (ONFH).

CONCLUSION

IrAEs associated with ICI therapy might be an emerging underlying disease of ONFH.

摘要

引言

免疫检查点抑制剂（ICIs）越来越多地用于治疗晚期转移性和免疫原性癌症。然而，这些疗法可能会导致免疫相关不良事件（irAEs），这需要给予高剂量糖皮质激素。

病例报告

一名52岁的转移性肾细胞癌男性接受了ICI治疗。两周后，他出现严重的irAEs，并接受了13个月的糖皮质激素治疗。在开始使用糖皮质激素21个月后，他因双侧髋部疼痛前来就诊，被诊断为双侧股骨头缺血性坏死（ONFH）。

结论

与ICI治疗相关的irAEs可能是ONFH一种新出现的潜在病因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/f1bdccd95eca/JOCR-14-36-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/db5891f5e4b4/JOCR-14-36-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/9b5befccb1cc/JOCR-14-36-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/b50b48864e7f/JOCR-14-36-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/f1bdccd95eca/JOCR-14-36-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/db5891f5e4b4/JOCR-14-36-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/9b5befccb1cc/JOCR-14-36-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/b50b48864e7f/JOCR-14-36-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac5/11327667/f1bdccd95eca/JOCR-14-36-g007.jpg

相似文献

1
Immune-related Adverse Event with Checkpoint Inhibitors Might Be an Emerging Underlying Disease of Steroid-related Osteonecrosis of the Femoral Head: A Case Report.免疫检查点抑制剂相关免疫不良事件可能是类固醇相关股骨头坏死的一种新的潜在病因：一例报告
J Orthop Case Rep. 2024 Aug;14(8):36-41. doi: 10.13107/jocr.2024.v14.i08.4638.
2
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.晚期泌尿生殖系统恶性肿瘤患者接受免疫检查点抑制剂治疗的结局特征。
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.
3
Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.病例报告：晚期肾细胞癌患者免疫检查点抑制剂相关膜性肾病的成功治疗。
Front Immunol. 2022 Jul 28;13:898811. doi: 10.3389/fimmu.2022.898811. eCollection 2022.
4
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗转移性肾和尿路上皮癌患者的条件性免疫毒性发生率。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000371.
5
Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗后免疫相关不良事件接受类固醇治疗的退伍军人的存活率。
JAMA Netw Open. 2023 Oct 2;6(10):e2340695. doi: 10.1001/jamanetworkopen.2023.40695.
6
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.免疫检查点抑制导致的罕见但严重的不良反应——孤立性中性粒细胞减少症。
J Immunother Cancer. 2019 Jul 5;7(1):169. doi: 10.1186/s40425-019-0648-3.
7
Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.免疫检查点抑制剂治疗患者的真实世界免疫相关不良事件的发生率和风险因素：一项全国性回顾性队列研究。
Cancer Lett. 2024 Aug 1;596:216998. doi: 10.1016/j.canlet.2024.216998. Epub 2024 Jun 1.
8
Bilateral corticosteroid-induced osteonecrosis of the femoral head detected at a 6-week interval.双侧皮质类固醇诱导的股骨头坏死，间隔6周检测到。
Springerplus. 2015 Nov 2;4:662. doi: 10.1186/s40064-015-1458-9. eCollection 2015.
9
Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.利妥昔单抗治疗的进展性尿路上皮癌患者使用帕博利珠单抗治疗后出现类固醇难治性皮肤和肺部毒性：一例报告
J Med Case Rep. 2021 Mar 19;15(1):124. doi: 10.1186/s13256-021-02670-3.
10
Delayed immune-related neutropenia with hepatitis by pembrolizumab.帕博利珠单抗所致的伴有肝炎的迟发性免疫相关性中性粒细胞减少症。
Immunotherapy. 2022 Feb;14(2):101-105. doi: 10.2217/imt-2021-0131. Epub 2021 Nov 11.

本文引用的文献

1
Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.免疫检查点抑制剂相关风湿免疫不良事件——2023 年更新。
Int J Mol Sci. 2023 Mar 15;24(6):5643. doi: 10.3390/ijms24065643.
2
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.欧洲泌尿外科学会肾癌指南：2022 年更新版。
Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.
3
Immune-related adverse events of checkpoint inhibitors.检查点抑制剂的免疫相关不良反应。
Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6.
4
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.NCCN 指南解读：免疫治疗相关毒性的管理，版本 1.2020。
J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
5
The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head.2019 年版股骨头坏死的协会研究循环性骨坏死分期系统。
J Arthroplasty. 2020 Apr;35(4):933-940. doi: 10.1016/j.arth.2019.11.029. Epub 2019 Nov 27.
6
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.联合免疫检查点抑制剂（抗 PD-1/PD-L1 加抗 CTLA-4）的安全性和耐受性：系统评价和荟萃分析。
BMC Cancer. 2019 Jun 10;19(1):559. doi: 10.1186/s12885-019-5785-z.
7
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
8
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.系统评价免疫检查点抑制剂随机试验中的不良事件。
Int J Cancer. 2019 Aug 1;145(3):639-648. doi: 10.1002/ijc.32132. Epub 2019 Feb 4.
9
Relationship of common variants in VEGFA gene with osteonecrosis of the femoral head: A Han Chinese population based association study.VEGFA 基因常见变异与股骨头坏死的关系：一项基于汉族人群的关联研究。
Sci Rep. 2018 Nov 1;8(1):16221. doi: 10.1038/s41598-018-34352-4.
10
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.肿瘤和免疫检查点抑制剂相关不良反应的分类特异性模式：系统评价。
Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286.